Multiple SclerosisNCT06102148
The Effect Of Proprioceptive Neuromuscular Facilitation Techniqueson in Patients With Multiple Sclerosis
A study testing PNF Group in people with Multiple Sclerosis, run by Deniz Çakır at 1 site in Turkey (Türkiye).
Trial summary
The aim of this study is to examine the effects of PNF techniques on pain, motor function, fatigue and quality of life. Read more about this study
- Who is it for?
- Ages 18 to 65 years
- Conditions the study is for
- Multiple Sclerosis
- What is being tested?
- PNF Group
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 44 participants
- Where
- 1 siteTurkey (Türkiye)
- Study dates
- 1 Nov 2021to 1 Nov 2022
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 65 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- a clinical diagnosis of Relapsing-Remitting MS (RRMS) as defined by McDonald criteria
- 18-65 years of age
- an Expanded Disability Status Scale (EDSS) score < 4
- relapse-free for the last 3 months
- cognitive impairment that was defined with mini mental test.
Who cannot join
- a history of different neurological diseases
- having any contraindication for exercise
- having orthopedic, vision, hearing, or perception problems.
Trial locations and contacts
1 site in 1 country.
Turkey (Türkiye)1 site
Ondokuz Mayıs University
Samsun, Samsun, 55270
About this study
Official title: The Effect Of Proprioceptive Neuromuscular Facilitation Techniqueson Pain, Motor Functions, Fatique and Health Related Quality of Life in Patients With Multiple Sclerosis: A Randomized, Single-blind Study.
The aim of this study is to examine the effects of PNF techniques on pain, motor function, fatigue and quality of life.
- Conditions
- Multiple Sclerosis
- Being tested
- PNF Group, Control Group
- Keywords
- Multiple Sclerosis, Proprioceptive Neuromuscular Facilitation, Pain, Motor Function, Fatigue, Quality of Life
- Medical subject headings
- Multiple Sclerosis, Pain, Fatigue
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
PNF GroupOther
Exercise training and PNF training
Control GroupOther
Exercise training
| Study group | Role | What they receive |
|---|---|---|
| PNF Group | Experimental | Not described Receives: Other: PNF Group |
| Control Group | Sham comparator | Not described Receives: Other: Control Group |
What is being measured
The primary outcome is the main question the study is designed to answer.
Visual Analogue Scale (VAS)
Pain
Measured: through study completion, an average of 1 year
Multiple Sclerosis Quality of Life-54 (MSQoL-54)
Quality of Life
Measured: through study completion, an average of 1 year
Fatigue Severity Scale and Fatigue Impact Scale (FIS)
Fatigue
Measured: through study completion, an average of 1 year
Timed Up and Go (TUG)
Mobility and Balance
Measured: through study completion, an average of 1 year
The Six-Minute Walk Test (6-MWT)
Functionality
Measured: through study completion, an average of 1 year
Hand Dexterity
Hand Dexterity
Measured: through study completion, an average of 1 year
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted26 Oct 2023
- Study start1 Nov 2021
- Primary completion1 Nov 2022
- Study completion1 Nov 2022
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Multiple SclerosisStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind
- Who is masked
- Investigator
- Enrolment
- 44 participants (actual)
Sponsor and investigators
- Lead sponsor
- Deniz Çakır
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor-investigator, Deniz Çakır, Ondokuz Mayıs University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06102148
- Sponsor's protocol ID
- 2021/413
- Status last verified
- Oct 2023
- First submitted
- 16 Oct 2023
- Last updated
- 5 Nov 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 5 Nov 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- The Effect Of Proprioceptive Neuromuscular Facilitation Techniqueson Pain, Motor Functions, Fatique and Health Related Quality of Life in Patients With Multiple Sclerosis: A Randomized, Single-blind Study.
- ClinicalTrials.gov ID
- NCT06102148
- Acronym / sponsor ID
- 2021/413
- Conditions
- Multiple Sclerosis
- Keywords
- Multiple Sclerosis, Proprioceptive Neuromuscular Facilitation, Pain, Motor Function, Fatigue, Quality of Life
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 44 participants (actual)
- Lead sponsor
- Deniz ÇakırUniversity, hospital or other
- Study start
- 1 Nov 2021 (actual)
- Primary completion
- 1 Nov 2022 (actual)
- Study completion
- 1 Nov 2022 (actual)
- First posted
- 26 Oct 2023 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The aim of this study is to examine the effects of PNF techniques on pain, motor function, fatigue and quality of life.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind (investigator)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| PNF Group | Experimental | Other: PNF Group |
| Control Group | Sham comparator | Other: Control Group |
Who may qualify
- Ages
- 18 to 65 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (5 listed)
- a clinical diagnosis of Relapsing-Remitting MS (RRMS) as defined by McDonald criteria
- 18-65 years of age
- an Expanded Disability Status Scale (EDSS) score < 4
- relapse-free for the last 3 months
- cognitive impairment that was defined with mini mental test.
Key exclusion criteria (3 listed)
- a history of different neurological diseases
- having any contraindication for exercise
- having orthopedic, vision, hearing, or perception problems.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| PNF GroupExercise training and PNF training | Other | PNF Group |
| Control GroupExercise training | Other | Control Group |
Primary outcome
Visual Analogue Scale (VAS)
Time frame: through study completion, an average of 1 year
Pain
Multiple Sclerosis Quality of Life-54 (MSQoL-54)
Time frame: through study completion, an average of 1 year
Quality of Life
Fatigue Severity Scale and Fatigue Impact Scale (FIS)
Time frame: through study completion, an average of 1 year
Fatigue
Timed Up and Go (TUG)
Time frame: through study completion, an average of 1 year
Mobility and Balance
The Six-Minute Walk Test (6-MWT)
Time frame: through study completion, an average of 1 year
Functionality
Hand Dexterity
Time frame: through study completion, an average of 1 year
Hand Dexterity
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 5 Nov 2026.
Related trials for Multiple Sclerosis
RecruitingPhase 2
Metformin as an add-on or Monotherapy in Treatment of Aging People With Multiple Sclerosis (MS)
Multiple Sclerosis
RecruitingObservational study
Pain Phenotypes in Individuals With Multiple Sclerosis
Multiple Sclerosis, Chronic Pain
Not yet recruiting
Evaluating the Effect of the Zeen Mobility Device on Clinical Practicality, Safety, and Impact (Via Assessments of Walking, Standing Tolerance, Balance, Endurance, Effort, and Participation in Daily Tasks) in an Outpatient Rehabilitation Setting for Individuals With Mobility Impairments.
Stroke, Parkinson's Disease (PD)
RecruitingPhase 3
Dalfampridine Combined With Physical Therapy for Mobility Impairment in Multiple Sclerosis
Multiple Sclerosis
RecruitingPhase 2
Targeting Agonists of Glucagon-like Peptide-1 Receptor for Multiple Sclerosis
Multiple Sclerosis
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing PNF Group in people with Multiple Sclerosis, run by Deniz Çakır at 1 site in Turkey (Türkiye).
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 5 Nov 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Turkey (Türkiye). Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Visual Analogue Scale (VAS) (time frame: through study completion, an average of 1 year). The study lists 6 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 5 Nov 2026.